New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study - Journal of Substance Abuse Treatment
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain - ScienceDirect
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
Understanding opioids in veterinary medicine
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
G protein signaling–biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists | PNAS
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
A Novel Kappa Opioid Receptor Agonist May Unlock New Treatment Strategies for Pain | Pain Research Forum
Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action | PNAS
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
Antagonists of the kappa opioid receptor - ScienceDirect
Mu Agonist Opioids and Kappa Opioids | Download Table
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression - ScienceDirect
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence - ScienceDirect
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
